The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis (LN). The study was supported by the Lupus Foundation of America.
Gazyva is an engineered humanized monoclonal antibody designed to attack CD20, a protein found on certain types of B cells that cause inflammation and damage to the kidneys. Gazyva works to deplete disease-causing B cells to protect the kidney from further damage and potentially prevent or delay progression to end-stage renal disease.
Nearly half of the people who received Gazyva plus standard therapy (mycophenolate mofetil and glucocorticoids) achieved a complete renal response, demonstrating a statistically significant and clinically meaningful improvement compared to those who received standard treatment alone. Furthermore, analysis showed consistent complete renal response across trial subgroups which highlights the potential of Gazyva to treat various patient populations with high unmet needs.
Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials.
This post was originally published on this site